Michael Hulse

Statistics

Publications

Citations

213

H-Index

Active since

1987

Affiliations

AstraZeneca (United Kingdom)(Current)

Michael Hulse is an author at AstraZeneca (United Kingdom) specializing in metastatic breast cancer treatment, hormone receptor - positive breast cancer, and cancer pharmacology.

Publications per year

1987–2025

Publications

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models

Hazel M. Weir, Robert H. Bradbury, Mandy Lawson et al. · Cancer Research · 2016 · 174 citations

Medicine, Oncology, Pharmacology +16

Essays in Honor of Elias Canetti

Sidney Rosenfeld, Michael Hulse · World Literature Today · 1987 · 18 citations

Humanities, Philosophy, Literary Theory +1

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in <i>SMARCA4</i> -Mutated Cancers

Michael Hulse, Min Wang, Chaoyi Xu et al. · Cancer Research · 2025 · 11 citations

Life Sciences, Cancer Biology, Molecular Biology +16

Abstract 3263: Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader

Michael Hulse, Anjana Agarwal, Min Wang et al. · Cancer Research · 2022 · 10 citations

Life Sciences, Molecular Biology, Oncology +12

1–4 of 4